Cilique 250/ 35 microgram tablets * Pharmacy Only: Prescription
Company:
Consilient Health LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
File name
HUG5367 Consilient Cillique A5 RMM v3[1]_1648829345.pdf
Reasons for updating
- Add New Doc
File name
HUG5367 A4 Cillique RMM Thromboembolism Checklist v7[1]_1648829301.pdf
Reasons for updating
- Add New Doc
Updated on 23 November 2021
File name
ie-spc-v0014-appr. 19.11.21_1637670057.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 23 November 2021
File name
02_P1371_Appr. 19.11.2021_1637669919.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 14 September 2021
File name
ie-spc-v0013 appr. 08.09.21_1631626252.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 14 September 2021
File name
P1294_Cilique appr. 14.09.21_1631624625.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
Updated on 09 January 2020
File name
P1088 - v007_1578579655.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Free text change information supplied by the pharmaceutical company
To include the following contraindication in section 2.1 of our package leaflet: ‘If you have cancer affected by sex hormones – such as some cancers of the breast or womb lining’
Updated on 16 October 2019
File name
common-spc-v005_1571238520.pdf
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.9 - Overdose
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Update of the product information in line with the reference product.
Updated on 16 October 2019
File name
P0889_v005_1571238415.pdf
Reasons for updating
- Change to Section 1 - what the product is
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
Free text change information supplied by the pharmaceutical company
Update of the product information in line with the reference product.
Updated on 11 March 2019
File name
Cilique-common-mockup_1552306928.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to date of revision
Updated on 11 March 2019
File name
Cilique-common-spc-clean-17.12.2018_1552307194.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 01 October 2018
File name
2. pil-mock-up_1538388932.pdf
Reasons for updating
- New PIL for new product
Updated on 01 October 2018
File name
1. common-spc-revised-17.11.2015_1538389083.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)